The Economic Survey 2024-25 reveals an expected increase in Goa's population to 15.96 lakh by 2025 but highlights worrying ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...

While the typical image of someone suffering a heart attack might be a man clutching his chest, heart disease is a major ...

Use of antidepressants for 6 or more years is linked to an increased risk for sudden cardiac death, but it’s unclear if the ...

Patients with MASLD had nearly twice the all-cause mortality rate as the general population, suggesting the need for multidisciplinary care to reduce excess mortality, researchers said.